Acemannan
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Acetylated polymannose (glucomannan) polysaccharide |
| Molecular Formula / CAS | Polysaccharide; native MW ranges from tens of kDa to over 1 MDa · CAS 110042-95-0 (reference standard) |
| Primary Botanical Source(s) | Aloe vera (Aloe barbadensis) |
| Plant Part | Inner leaf gel |
| Typical Content | The principal bioactive polysaccharide of aloe vera gel, alongside other aloe polysaccharide fractions |
| Solubility / Format | Water-soluble polysaccharide; available as standardised extract powders |
| Sourcing Status | Product-live — genuine match via Herbuno’s aloe vera extract line |
| Buy from Herbuno | Acemannan 80% Powder (Aloe Vera Extract) |
Name origin: Acemannan takes its name from its chemical composition — an acetylated mannan polysaccharide — describing both its acetyl-group substitution pattern and its mannose-based sugar backbone. Traditional use: Aloe vera has one of the longest continuously documented traditional-medicine histories of any plant in the HerbIQ index, used for wound healing and skin conditions across Egyptian, Greek and Chinese medical traditions for more than 2,000 years, long before acemannan was identified as a specific active constituent of the gel. Research trajectory: Acemannan was isolated and characterised as aloe vera’s principal bioactive polysaccharide in the 1980s, and early research focused heavily on immunomodulatory and antiviral applications, including veterinary use as an approved immunostimulant for cancer treatment in dogs and cats; research since has expanded into wound healing, oral mucosal health, and dental/bone tissue regeneration, with growing interest in acemannan as a standalone biomaterial for tissue engineering distinct from whole aloe gel. Commercial source: Aloe vera inner leaf gel is the standard commercial source of acemannan, and Herbuno’s standardised extract reflects this well-established, genuine botanical match.
Evidence for Acemannan Applications
Acemannan is a β-(1,4)-linked acetylated polymannose that primarily exerts its documented immunomodulatory effects by activating innate immune cells — specifically macrophages and dendritic cells — triggering production of cytokines including IL-1, IL-6, IL-12, TNF-alpha and various colony-stimulating factors. A pharmacodynamics review notes that topical acemannan, particularly in combination with chitosan, accelerates wound closure by promoting granular tissue formation and driving macrophage M2 polarisation, which reverses local inflammation and accelerates re-epithelialisation (Foster et al. 2021). Claim strength: Moderate.
A randomised clinical trial in patients with recurrent oral aphthous ulceration directly compared 0.5% acemannan gel against 0.1% triamcinolone acetonide (a standard corticosteroid treatment) and placebo carrier gel, finding acemannan significantly more effective than placebo at reducing ulcer size and pain, though less effective than the steroid comparator; notably, no allergic reactions or adverse blood test changes were observed with acemannan use, supporting it as an option for patients wishing to avoid steroid medication (Bhalang et al. 2013). Claim strength: Moderate.
A recent case report describes successful use of an acemannan-enriched glycolipid sphere dressing in treating a diabetic foot ulcer, building on documented evidence that acemannan modulates macrophage activity, mitigates inflammatory cytokine storms, and facilitates inflammation resolution to support tissue regeneration in chronic wound contexts (et al. 2025). This remains a single case report rather than a controlled trial, illustrating an emerging clinical application area. Claim strength: Emerging.
Acemannan has also been investigated for dental and bone tissue applications, including stimulation of dental pulp cell proliferation, differentiation and dentin formation, and use as a direct pulp capping material in paediatric dentistry, alongside documented in-vitro antiviral activity against HIV-1 through inhibition of viral replication. This breadth of application reflects acemannan’s general immunomodulatory and tissue-regenerative mechanism rather than a single narrowly validated use. Claim strength: Emerging.
A meaningful sourcing consideration for acemannan is that its native molecular weight in aloe vera gel varies enormously — from tens of kilodaltons to over a million daltons — depending on plant source, age and extraction method, and this molecular weight variation is understood to influence bioactivity. The defined reference-standard molecular weight used by chemical suppliers for analytical purposes represents a specific characterised oligomer rather than the full range of polysaccharide sizes present in a natural extract. Claim strength: Moderate.
Dosage & Formulator Specification
The oral aphthous ulceration trial used 0.5% acemannan gel applied topically three times daily for seven days; no established oral/ingestible human dosing range exists for acemannan, reflecting its research base being concentrated predominantly on topical and mucosal applications rather than systemic supplementation.
Analytical characterisation of acemannan is more complex than most small-molecule HerbIQ compounds, since it is a polysaccharide with variable native molecular weight; formulators should request documentation of both acemannan percentage and molecular weight distribution where relevant to the intended application, since bioactivity has been linked to molecular weight in addition to raw concentration.
Because acemannan is water-soluble and heat- and pH-sensitive to some degree, formulators should consider processing conditions carefully when incorporating it into finished topical or oral-care products, and should request supplier stability data specific to their intended formulation base and shelf-life requirements.
Regulatory positioning for acemannan follows established aloe vera food, cosmetic and botanical-ingredient precedent in most markets, given aloe vera’s multi-thousand-year traditional use history; acemannan additionally carries veterinary drug approval in some jurisdictions as an injectable immunostimulant for cancer treatment in companion animals, a distinct regulatory context from its dietary supplement and cosmetic ingredient use in humans.
Frequently Asked Questions — Acemannan
Acemannan is the principal bioactive polysaccharide found in aloe vera inner leaf gel, credited with much of the immunomodulatory and wound-healing activity traditionally attributed to aloe vera. It was isolated and characterised as a specific compound in the 1980s.
A randomised clinical trial in patients with recurrent oral aphthous ulceration found topical 0.5% acemannan gel significantly more effective than placebo at reducing ulcer size and pain, though less effective than a standard corticosteroid treatment, with no allergic reactions or adverse blood test changes observed.
As a natural polysaccharide, acemannan’s molecular weight in aloe vera gel ranges from tens of kilodaltons to over a million daltons depending on the plant source, age and extraction method used. This variability is understood to influence its bioactivity, which is why formulators should request molecular weight documentation alongside concentration data where relevant.
Yes. Injectable acemannan has veterinary drug approval in some jurisdictions as an immunostimulant used alongside surgery and radiation therapy for certain cancers in dogs and cats, a distinct regulatory and clinical context from its use as a dietary supplement or cosmetic ingredient in human products.
Related compounds: Salicin, Bromelain